Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| DYNEGY, Inc. (NASDAQ: DYN) | Delayed: 15.90 -0.17 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.07 | 52 Week High | $22.01 | |||
| Open | $15.99 | 52 Week Low | $7.01 | |||
| Day High | $16.34 | P/E | N/A | |||
| Day Low | $15.70 | EPS | $0.00 | |||
| Volume | 320,683 | |||||
